|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Development of PARP inhibitors in ontology 显示文摘 | RODON J IN1ESTA MD PAPADOPOULOS K | 2009 | Expert Opin lnvestig Drugs2009，18，1： | 1 |
| 2 | Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors 显示文摘 | Dienstmarm R Rodon J Serra V | 2014 | Molecular cancer therapeutics2014，13，5： | 1 |
| 3 | Phase I,dose-escalation study of BKM120, an oral pan-Class I PI3Kinhibitor, in patients with advanced solid tumors 显示文摘 | Bendell JC Rodon J Burris HA | 2012 | J ClinOncol2012，30，3： | 1 |
| 4 | Phase Ⅰ,dose-escalation study of BKM 120,an oral pan-Class Ⅰ P13K inhibitor,in patients with advanced solid tumors显示文摘 | Bendell JC Rodon J Burris HA | 2012 | J Clin Oncol2012，30，3： | 1 |
| 5 | First-in-human dose study of the Novel transforming growth factor-β receptor Ⅰ kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma显示文摘 | Rodon J Carducci MA Sepulveda-Sanchez JM | 2014 | Clin Cancer Res2014，，： | 1 |
| 6 | Pilot studies for personalized cancer medicine: focusing on the patient for treatment selec; tion 显示文摘 | De Mattos-Arruda L Rodon J | 2013 | Oncologist2013，18，11： | 1 |
| 7 | Phase I, dose- escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors显示文摘 | Bendell JC Rodon J Burris H A | 2012 | Journal of Clinical Oncology2012，30，3： | 1 |
| 8 | Nearly zero inclination geosynchronous SAR mission analysis with long integration time for earth observation 显示文摘 | RUIZ RODON J BROQUETAS A MAKHOUL E | 2014 | IEEE Transactions of Geoscience and Remote Sensing2014，52，10： | 1 |
| 9 | A first-in-human phase Ⅰ study of BKM120,an oral pan-class I PI3K inhibitor,in patients (pts) with advanced solid tumors显示文摘 | Baselga J Rodon J Burris HA | | 0，，15： | 1 |
| 10 | First in-human phase Ⅰ study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors显示文摘 | Baselga J Jonge DE Rodon J | | 0，，15： | 1 |
| 11 | Phase; , dose-escala tion study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors显示文摘 | Bendell JC Rodon J Burris HA | 2012 | J Clin Oncol2012，30，3： | 1 |
| 12 | A process-stake-holder analysis of B2B industry standardization显示文摘 | Rodon J Ramis-Pujol J Christiaanse E | 2007 | Jour-nal of Enterprise Information Management2007，20，1： | 1 |
| 13 | A process - stakeholder analysis of B2B industry standardization 显示文摘 | Rodon J Ramis -Pujol J Christiaanse E | 2007 | Journal of Enterprise Information Management2007，20，1： | 1 |
| 14 | A phase Ⅰ pharmakinetic and pharmacodynamic study of AMG 479,a fully monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-IR) in advanced solid tumors显示文摘 | Tolcher A Rothenberg M Rodon J | 2007 | J Clin Oncol2007，25，： | 1 |
| 15 | A process - stakeholder analysis of B2B industry standardization 显示文摘 | RODON J RAMIS - PUJOL J CHRISTIAANSE E | 2007 | Journal of Enterprise Information Management2007，20，1： | 1 |
| 16 | Genomic aberra- tions in the FGFR pathway: opportunities for targeted therapies in solid tumors显示文摘 | Dienstmann R Rodon J Prat A | 2014 | Ann Oncol2014，25，3： | 1 |
| 17 | Picking the point of inhibition:a comparative review of PI3K/AKT/mTOR pathway inhibitors 显示文摘 | DIENSTMANN R RODON J SERRA V | 2014 | Mol Cancer Ther2014，13，5： | 1 |
| 18 | Efficacy of melphalan and predni- sone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01 /01 trial 显示文摘 | Hulin C Facon T Rodon P Pegourie B Benboubker L Doyen C Dib M Guillerm G SalIes B Esehard JP Lenain P Casas- sus P Azais I Decaux O Garderet L Mathiot C Fontan J Lafon I Virion JM Moreau P | 2009 | J Clin On- col2009，27，22： | 1 |
| 19 | Phase I dose-escalation and - expansion study of buparlisib (BKM120), an oral pan-C/ass I PI3K inhibitor, in patients with advanced solid tumors显示文摘 | Rodon J Brana I Siu LL | 2014 | Invest New Drugs2014，32，4： | 1 |
| 20 | Development ofPI3K inhibitors: lessons learned from early clinical trials显示文摘 | Rodon J Dienstmann R Serra V | 2013 | Nat Rev Clin Oncol2013，10，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员